Center for Inherited Disease Research to Use Illumina Whole-Genome Genotyping Solutions to Support Study for Finland-United States Type 2 Diabetes Collaboration.
Illumina Inc. announced that it is partnering with the Center for Inherited Disease Research to use the Sentrix(R) HumanHap300 BeadChip and Infinium(TM) Assay for a pilot study of Type 2 Diabetes. One goal of this study is to evaluate the Illumina technology for possible adoption as the standard platform for CIDR's genome-wide association service to be offered to the scientific community in the spring of 2006.
